12:07 PM EDT, 03/13/2024 (MT Newswires) -- The US Food and Drug Administration's staff on Wednesday raised concerns about whether the cancer cell therapies of Johnson & Johnson ( JNJ ) and Bristol Myers Squibb ( BMY ) would benefit adult patients with myeloma, a type of blood cancer, due to higher rate of early deaths in their respective late-stage trials, according to briefing documents.

The health regulator's oncologic drugs advisory committee will discuss their concerns over Janssen's Carvykti and Bristol Myers' Abecma on Friday.

Neither Johnson & Johnson ( JNJ ) nor Bristol Myers immediately responded to requests for comment by MT Newswires.

Price: 162.32, Change: -0.43, Percent Change: -0.26